AUPO755097A0 - Receptor agonist and antagonist - Google Patents

Receptor agonist and antagonist

Info

Publication number
AUPO755097A0
AUPO755097A0 AUPO7550A AUPO755097A AUPO755097A0 AU PO755097 A0 AUPO755097 A0 AU PO755097A0 AU PO7550 A AUPO7550 A AU PO7550A AU PO755097 A AUPO755097 A AU PO755097A AU PO755097 A0 AUPO755097 A0 AU PO755097A0
Authority
AU
Australia
Prior art keywords
antagonist
receptor agonist
protein
coupled receptors
modulate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPO7550A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
Original Assignee
University of Queensland UQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Queensland UQ filed Critical University of Queensland UQ
Priority to AUPO7550A priority Critical patent/AUPO755097A0/en
Publication of AUPO755097A0 publication Critical patent/AUPO755097A0/en
Priority to AU80926/98A priority patent/AU744991B2/en
Priority to ES98930536T priority patent/ES2294816T3/es
Priority to PT98930536T priority patent/PT1017713E/pt
Priority to AT98930536T priority patent/ATE377606T1/de
Priority to DE69838678T priority patent/DE69838678T2/de
Priority to DK98930536T priority patent/DK1017713T3/da
Priority to US12/045,088 priority patent/USRE41287E1/en
Priority to JP50515499A priority patent/JP4686696B2/ja
Priority to HK01100346.0A priority patent/HK1029595B/en
Priority to PCT/AU1998/000490 priority patent/WO1999000406A1/en
Priority to US09/446,109 priority patent/US6821950B1/en
Priority to EP98930536A priority patent/EP1017713B1/en
Priority to US10/937,852 priority patent/US20060160726A1/en
Priority to CY20081100033T priority patent/CY1107133T1/el
Priority to US12/193,943 priority patent/US20090203760A1/en
Priority to US13/348,869 priority patent/US20130005644A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
AUPO7550A 1997-06-25 1997-06-25 Receptor agonist and antagonist Abandoned AUPO755097A0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
AUPO7550A AUPO755097A0 (en) 1997-06-25 1997-06-25 Receptor agonist and antagonist
EP98930536A EP1017713B1 (en) 1997-06-25 1998-06-25 CYCLIC ANTAGONISTS OF C5a RECEPTORS AND G PROTEIN-COUPLED RECEPTORS
JP50515499A JP4686696B2 (ja) 1997-06-25 1998-06-25 Ｃ５ａ受容体およびＧタンパク質結合受容体の環状アゴニストおよびアンタゴニスト
PCT/AU1998/000490 WO1999000406A1 (en) 1997-06-25 1998-06-25 CYCLIC AGONISTS AND ANTAGONISTS OF C5a RECEPTORS AND G PROTEIN-COUPLED RECEPTORS
PT98930536T PT1017713E (pt) 1997-06-25 1998-06-25 Antagonistas cíclicos de receptores de c5a e de receptores acoplados à proteína g
AT98930536T ATE377606T1 (de) 1997-06-25 1998-06-25 Zyklische antagonisten der c5a rezeptoren sowie der g-protein gekoppelten rezeptoren
DE69838678T DE69838678T2 (de) 1997-06-25 1998-06-25 ZYKLISCHE ANTAGONISTEN DER C5a REZEPTOREN SOWIE DER G-PROTEIN GEKOPPELTEN REZEPTOREN
DK98930536T DK1017713T3 (da) 1997-06-25 1998-06-25 Cykliske antagonister af C5a-receptorer og G-protein-koblede receptorer
US12/045,088 USRE41287E1 (en) 1997-06-25 1998-06-25 Cyclic agonists and antagonists of C5A receptors and G Protein-coupled receptors
AU80926/98A AU744991B2 (en) 1997-06-25 1998-06-25 Cyclic agonists and antagonists of C5a receptors and G protein-coupled receptors
HK01100346.0A HK1029595B (en) 1997-06-25 1998-06-25 Cyclic antagonists of c5a receptors and g protein-coupled receptors
ES98930536T ES2294816T3 (es) 1997-06-25 1998-06-25 Antagonistas ciclicos de receptores de c5a y receptores acoplados a proteinas g.
US09/446,109 US6821950B1 (en) 1997-06-25 1998-06-25 Cyclic agonists and antagonists of C5a receptors and G protein-coupled receptors
US10/937,852 US20060160726A1 (en) 1997-06-25 2004-09-10 Cyclic agonists and antagonists of C5a receptors and G protein-coupled receptors
CY20081100033T CY1107133T1 (el) 1997-06-25 2008-01-10 Κυκλικοι ανταγωνιστες των υποδοχεων c5a και συζευγμενοι με πρωτεϊνη g υποδοχεις
US12/193,943 US20090203760A1 (en) 1997-06-25 2008-08-19 CYCLIC AGONISTS AND ANTAGONISTS OF C5a RECEPTORS AND G PROTEIN-COUPLED RECEPTORS
US13/348,869 US20130005644A1 (en) 1997-06-25 2012-01-12 Cyclic agonists and antagonists of c5a receptors and g protein-coupled receptors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPO7550A AUPO755097A0 (en) 1997-06-25 1997-06-25 Receptor agonist and antagonist

Publications (1)

Publication Number Publication Date
AUPO755097A0 true AUPO755097A0 (en) 1997-07-17

Family

ID=3801840

Family Applications (2)

Application Number Title Priority Date Filing Date
AUPO7550A Abandoned AUPO755097A0 (en) 1997-06-25 1997-06-25 Receptor agonist and antagonist
AU80926/98A Ceased AU744991B2 (en) 1997-06-25 1998-06-25 Cyclic agonists and antagonists of C5a receptors and G protein-coupled receptors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU80926/98A Ceased AU744991B2 (en) 1997-06-25 1998-06-25 Cyclic agonists and antagonists of C5a receptors and G protein-coupled receptors

Country Status (11)

Country Link
US (5) US6821950B1 (enExample)
EP (1) EP1017713B1 (enExample)
JP (1) JP4686696B2 (enExample)
AT (1) ATE377606T1 (enExample)
AU (2) AUPO755097A0 (enExample)
CY (1) CY1107133T1 (enExample)
DE (1) DE69838678T2 (enExample)
DK (1) DK1017713T3 (enExample)
ES (1) ES2294816T3 (enExample)
PT (1) PT1017713E (enExample)
WO (1) WO1999000406A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO755097A0 (en) * 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
AUPQ339899A0 (en) 1999-10-13 1999-11-04 University Of Queensland, The Novel molecules
ES2353077T3 (es) 2000-08-10 2011-02-25 Mitsubishi Tanabe Pharma Corporation Derivados de urea con sustitución en posición 3 y uso medicinal de los mismos.
CN102050758A (zh) 2000-09-14 2011-05-11 田边三菱制药株式会社 酰胺衍生物及其制备药物的用途
AUPR833401A0 (en) * 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
EP1492811B1 (en) 2002-03-19 2011-09-21 Cincinnati Childrens's Hospital Medical Center Muteins of the c5a anaphylatoxin, nucleic acid molecules encoding such muteins, and pharmaceutical uses of muteins of the c5a anaphylatoxin
US20040014782A1 (en) * 2002-03-29 2004-01-22 Krause James E. Combination therapy for the treatment of diseases involving inflammatory components
AUPS160602A0 (en) * 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
AU2002950657A0 (en) 2002-08-08 2002-09-12 Alchemia Limited Derivatives of monosaccharides for drug discovery
AU2002951995A0 (en) * 2002-10-11 2002-10-31 Alchemia Limited Classes of compounds that interact with gpcrs
AU2003266858B2 (en) * 2002-10-11 2006-09-14 Vast Bioscience Pty Limited Classes of compounds that interact with GPCRs
AU2002952086A0 (en) * 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis
US7410945B2 (en) * 2002-10-16 2008-08-12 The University Of Queensland Treatment of inflammatory bowel disease
AU2002952129A0 (en) * 2002-10-17 2002-10-31 The University Of Queensland Treatment of hypersensitivity conditions
AU2003902354A0 (en) * 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
AU2003902586A0 (en) * 2003-05-26 2003-06-12 The University Of Queensland Treatment of burns
WO2005014849A2 (en) * 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
EP1498422A1 (de) * 2003-07-17 2005-01-19 Jerini AG C5a-Rezeptor-Antagonisten
WO2006037159A1 (en) * 2004-10-04 2006-04-13 Alchemia Limited Selective inhibitors
AU2006205830A1 (en) * 2005-01-17 2006-07-20 Jerini Ag C5a receptor antagonists
US20090117171A1 (en) * 2005-03-11 2009-05-07 Cedric Francois Compositions and methods for treatment of macular degeneration and related conditions
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
US20070292421A1 (en) * 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
EP2148691B1 (en) 2007-02-05 2015-05-20 Apellis Pharmaceuticals, Inc. Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
WO2009015087A2 (en) * 2007-07-20 2009-01-29 Potentia Pharmaceuticals, Inc. Compositions and methods for treatment of trauma
US20110190221A1 (en) * 2008-03-28 2011-08-04 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
EP2304809A2 (en) * 2008-07-02 2011-04-06 Saint-Gobain Performance Plastics Chaineux Framed device, seal, and method for manufacturing same
RS64039B1 (sr) 2008-11-10 2023-04-28 Alexion Pharma Inc Metode i kompozicije za lečenje poremećaja povezanih sa komplementom
EP2525814A4 (en) * 2010-01-22 2013-09-11 Univ Louisville Res Found METHODS OF TREATING OR PREVENTING PERIODONTITIS AND PARODONTIST-RELATED DISEASES
KR101800913B1 (ko) 2010-04-30 2017-12-20 알렉시온 파마슈티칼스, 인코포레이티드 항-c5a 항체들과 이 항체들을 이용하는 방법
US9895411B2 (en) 2010-06-29 2018-02-20 San Diego State University Research Foundation Analogs of C5a and methods of using same
EP2468295A1 (en) * 2010-12-21 2012-06-27 Affiris AG Vaccines based on peptides of the complement protein C5a
CN103796667A (zh) 2011-06-22 2014-05-14 艾普莱斯制药公司 用补体抑制剂治疗慢性障碍的方法
US9289467B2 (en) 2011-08-10 2016-03-22 Case Western Reserve University Compositions and methods for treating bone conditions
WO2014043223A1 (en) * 2012-09-11 2014-03-20 Hospital For Special Surgery Irhom2 inhibition for the treatment of complement mediated disorders
CA2891673C (en) 2012-11-15 2025-10-07 Apellis Pharmaceuticals Inc Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
JP2016516752A (ja) * 2013-04-02 2016-06-09 ザ スクリプス リサーチ インスティテュート アテローム性動脈硬化症の治療および予防のための環状ペプチドの使用
AU2014306002B2 (en) 2013-08-07 2017-05-25 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
JP6968787B2 (ja) 2015-10-07 2021-11-17 アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals, Inc. 投与レジメン
EP3491005A1 (en) 2016-07-29 2019-06-05 Pfizer Inc Cyclic peptides as c5 a receptor antagonists
US20200057046A1 (en) 2016-10-27 2020-02-20 Alexion Pharmaceuticals, Inc. Assay for c5b-9 deposition in complement-associated disorders
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
PL3411400T3 (pl) 2017-04-03 2021-12-20 Inflarx Gmbh Leczenie chorób zapalnych za pomocą inhibitorów aktywności c5a
US11040107B2 (en) 2017-04-07 2021-06-22 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
JP7502865B2 (ja) 2017-06-23 2024-06-19 インフラルクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｃ５ａ活性のインヒビターでの炎症性疾患の処置
KR20240167712A (ko) 2017-12-15 2024-11-27 아펠리스 파마슈티컬스 인코포레이티드 투여 요법 및 관련 조성물 및 방법
WO2021067526A1 (en) 2019-10-02 2021-04-08 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
AU2020438234A1 (en) 2020-03-27 2022-09-29 Inflarx Gmbh Inhibitors of C5a for the treatment of corona virus infection
WO2021231720A1 (en) 2020-05-15 2021-11-18 Alexion Pharmaceuticals, Inc. Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease
WO2024238421A1 (en) 2023-05-12 2024-11-21 Alexion Pharmaceuticals, Inc. Use of biomarkers for the identification and treatment of complement-mediated disorders
WO2024238422A1 (en) 2023-05-12 2024-11-21 Alexion Pharmaceuticals, Inc. Use of a panel of lectins for detection of complement biomarkers in urine extracellular vesicles
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5386011A (en) * 1990-12-27 1995-01-31 Abbott Laboratories Hexapeptide anaphylatoxin-receptor ligands
FI962319A7 (fi) 1993-12-06 1996-06-03 Novartis Ag C5a-reseptorin antagonistit, joilla ei ole olennaista agonistiaktiivis uutta
US5807824A (en) 1993-12-06 1998-09-15 Ciba-Geigy Corporation C5A receptor antagonists having substantially no agonist activity
US5614370A (en) * 1994-03-18 1997-03-25 Merck & Co., Inc. Assay to identify human C5a antagonists and agonists
US5696230A (en) 1994-08-31 1997-12-09 The Board Of Regents Of The University Of Nebraska High-affinity response-selective C-terminal analogs of C5a anaphylatoxin
AUPO755097A0 (en) 1997-06-25 1997-07-17 University Of Queensland, The Receptor agonist and antagonist
AUPR833401A0 (en) 2001-10-17 2001-11-08 University Of Queensland, The G protein-coupled receptor antagonists
AUPS160602A0 (en) * 2002-04-08 2002-05-16 University Of Queensland, The Therapeutic method
AU2002952086A0 (en) * 2002-10-16 2002-11-07 The University Of Queensland Treatment of osteoarthritis

Also Published As

Publication number Publication date
CY1107133T1 (el) 2012-10-24
USRE41287E1 (en) 2010-04-27
EP1017713B1 (en) 2007-11-07
DE69838678T2 (de) 2008-10-30
US20060160726A1 (en) 2006-07-20
EP1017713A4 (en) 2002-07-24
ES2294816T3 (es) 2008-04-01
JP4686696B2 (ja) 2011-05-25
PT1017713E (pt) 2007-12-18
HK1029595A1 (en) 2001-04-06
AU744991B2 (en) 2002-03-07
US20130005644A1 (en) 2013-01-03
AU8092698A (en) 1999-01-19
US6821950B1 (en) 2004-11-23
JP2002508767A (ja) 2002-03-19
DE69838678D1 (de) 2007-12-20
DK1017713T3 (da) 2008-02-11
EP1017713A1 (en) 2000-07-12
WO1999000406A1 (en) 1999-01-07
ATE377606T1 (de) 2007-11-15
US20090203760A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
AUPO755097A0 (en) Receptor agonist and antagonist
YU34898A (sh) Antagonisti ccr-3 receptora
AU2962295A (en) Cannabinoid receptor antagonists
NO983431L (no) Anti-klöemidler
PT800519E (pt) Compostos moduladores de receptores de esteroides e metodos
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
EA200101177A1 (ru) Производные индола в качестве антагонистов прогестерона
MX9704640A (es) Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion.
MY137457A (en) Cyclic peptides having melanocortin-4 receptor agonist activity
EA200200646A1 (ru) Соединения мочевины, обладающие активностью антагонистов мускариновых рецепторов
ATE299494T1 (de) Carbamat-derivate als muscarin-rezeptor antonisten
AU2001245209A1 (en) Screening methods for bone morphogenetic mimetics
CO5460266A1 (es) Novedosos analogos de la somatostatina
SE9702002D0 (sv) Novel compounds
AUPN646795A0 (en) Neuropeptide Y-Y5 receptor
SE9702794D0 (sv) New compounds
PT1042320E (pt) Novos compostos que sao antagonistas de receptores duplos de ourinoceptores p2 e de proteina g 7-transmembranar
DE60015187D1 (de) Urotensin-ii rezeptorantagonisten
EA200000197A1 (ru) 2-ациламинопропанамины в качестве антагонистов рецепторов тахикининов
DE69526738D1 (de) Endothelin-rezeptor-antagonisten
DK1056850T3 (da) Biotinbindende receptormolekyler
UA97251C2 (ru) Соединения как модуляторы опиоидного рецептора
SE0303418D0 (sv) New use 1